{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:42Z","timestamp":1790931342729,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08055-2","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:38:53Z","timestamp":1784961533000},"page":"7248-7257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Standardized FDG-PET interpretation during CAR T-cell therapy in R\/R DLBCL: a DESCAR-T study"],"prefix":"10.1007","volume":"53","author":[{"given":"Yassine","family":"Al Tabaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Palard-Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Tordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Lesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Kanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Van Zele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-2942","authenticated-orcid":false,"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"8055_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"8055_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"8055_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"8055_CR4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295\u2013312.","journal-title":"Am J Hematol"},{"key":"8055_CR5","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet (London, England). 2022;399:2294\u2013308.","journal-title":"Lancet (London, England)"},{"key":"8055_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354.","journal-title":"N Engl J Med"},{"key":"8055_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","volume":"46","author":"P Sesques","year":"2021","unstructured":"Sesques P, Tordo J, Ferrant E, et al. Prognostic impact of 18F-FDG PET\/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells. Clin Nucl Med. 2021;46:627\u201334.","journal-title":"Clin Nucl Med"},{"key":"8055_CR8","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:3268\u201376.","journal-title":"Blood Adv"},{"key":"8055_CR9","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607\u201315.","journal-title":"Blood Adv"},{"key":"8055_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06427-6","author":"E Marchal","year":"2023","unstructured":"Marchal E, Palard-Novello X, Lhomme F, et al. Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-023-06427-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8055_CR11","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1182\/blood.2023021620","volume":"143","author":"FL Locke","year":"2024","unstructured":"Locke FL, Oluwole OO, Kuruvilla J, et al. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood. 2024;143:2464\u201373.","journal-title":"Blood"},{"key":"8055_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3231","volume":"42","author":"HS Ababneh","year":"2024","unstructured":"Ababneh HS, Ng AK, Abramson JS, et al. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed\/refractory large B-cell lymphoma. Hematol Oncol. 2024;42:e3231.","journal-title":"Hematol Oncol"},{"key":"8055_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","volume":"6","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A, Roddie C, Kirkwood AA, et al. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv. 2022;6:321\u20136.","journal-title":"Blood Adv"},{"key":"8055_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05551-5","author":"D Cohen","year":"2021","unstructured":"Cohen D, Luttwak E, Beyar-Katz O, et al. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05551-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8055_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3324\/haematol.2021.280550","volume":"108","author":"J Galtier","year":"2023","unstructured":"Galtier J, Vercellino L, Chartier L, et al. Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed\/refractory large B-cell lymphoma receiving CAR T cells. Haematologica. 2023;108:171\u201380.","journal-title":"Haematologica"},{"key":"8055_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00259-023-06554-0","volume":"51","author":"C-A Voltin","year":"2024","unstructured":"Voltin C-A, Paccagnella A, Winkelmann M, et al. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy. Eur J Nucl Med Mol Imaging. 2024;51:1361\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8055_CR17","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8055_CR18","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.3324\/haematol.2022.282345","volume":"108","author":"JL Crombie","year":"2023","unstructured":"Crombie JL, Jacobson CA, Redd R, et al. Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy. Haematologica. 2023;108:3433\u20137.","journal-title":"Haematologica"},{"key":"8055_CR19","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1182\/bloodadvances.2023010665","volume":"7","author":"JW de Boer","year":"2023","unstructured":"de Boer JW, Pennings ERA, Kleinjan A, et al. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET\/CT after CD19-directed CAR T-cell therapy. Blood Adv. 2023;7:6710\u20136.","journal-title":"Blood Adv"},{"key":"8055_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/bjr\/tqae178","volume":"97","author":"L Vercellino","year":"2024","unstructured":"Vercellino L, Betterki S, Blanc E, et al. Patterns of metabolic response in patients receiving commercial CAR T-cells for relapsing\/refractory aggressive B cells lymphoma. Br J Radiol. 2024;97:1755\u201364.","journal-title":"Br J Radiol"},{"key":"8055_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70091","volume":"9","author":"J Galtier","year":"2025","unstructured":"Galtier J, Mesguich C, Sesques P, et al. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry. HemaSphere. 2025;9:e70091.","journal-title":"HemaSphere"},{"key":"8055_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00895-7","volume":"13","author":"WG Breen","year":"2023","unstructured":"Breen WG, Young JR, Hathcock MA, et al. Metabolic PET\/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 2023;13:127.","journal-title":"Blood Cancer J"},{"key":"8055_CR23","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","volume":"6","author":"A Al Zaki","year":"2022","unstructured":"Al Zaki A, Feng L, Watson G, et al. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy. Blood Adv. 2022;6:2867\u201371.","journal-title":"Blood Adv"},{"key":"8055_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40364-024-00650-5","volume":"12","author":"L-S Sheng","year":"2024","unstructured":"Sheng L-S, Shen R, Yan Z-X, et al. 18F-FDG PET\/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burden. Biomark Res. 2024;12:104.","journal-title":"Biomark Res"},{"key":"8055_CR25","doi-asserted-by":"crossref","unstructured":"Farolfi A, Casadei B, Malizia C, et al. Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study. J Nucl Med Off Publ Soc Nucl Med. April 2025:jnumed.125.269670.","DOI":"10.2967\/jnumed.125.269670"},{"key":"8055_CR26","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1007\/s00259-025-07154-w","volume":"52","author":"S Malmon","year":"2025","unstructured":"Malmon S, Casasnovas O, Fournier M, et al. Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed\/refractory lymphomas: results from the GATA study. Eur J Nucl Med Mol Imaging. 2025;52:2856\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8055_CR27","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.21.00377","volume":"39","author":"MJ Frank","year":"2021","unstructured":"Frank MJ, Hossain NM, Bukhari A, et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J Clin Oncol. 2021;39:3034\u201343.","journal-title":"J Clin Oncol"},{"key":"8055_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","volume":"41","author":"BJ Sworder","year":"2023","unstructured":"Sworder BJ, Kurtz DM, Alig SK, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2023;41:210-225.e5.","journal-title":"Cancer Cell"},{"key":"8055_CR29","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/bloodadvances.2022009426","volume":"7","author":"EA Dean","year":"2023","unstructured":"Dean EA, Kimmel GJ, Frank MJ, et al. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2023;7:4608\u201318.","journal-title":"Blood Adv"},{"issue":"232","key":"8055_CR30","volume":"2025","author":"P Sesques","year":"1990","unstructured":"Sesques P, Manson G, Dubois S, et al. Large B-cell lymphoma: The LYSA pragmatic guidelines. Eur J Cancer Oxf Engl. 1990;2025(232):116070.","journal-title":"Eur J Cancer Oxf Engl"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08055-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:16Z","timestamp":1790929936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08055-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8055"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08055-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was undertaken in accordance with the Declaration of Helsinki. The DESCAR-T registry complies with the French legal requirements of Research Not Involving the Human Person and data reuse (RNIPH-MR004). As such, before their enrollment in the DESCAR-T registry, all patients or their legal representatives were individually informed about the non-interventional use of personal data. The DESCAR-T registry is registered under the ClinicalTrials.gov identifier NCT04328298.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients included in this study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PS has received honoraria from AbbVie, BMS, Chugai, J&J, Kite\/Gilead, Novartis, Astrazeneca, and Roche. GC has received honoraria from Roche, Abbvie, BMS, Novartis, Jansen, Gilead, Takeda and acted as consultant for Roche, Abbvie, BMS, Novartis, MabQi, Ownard therapeutics. RH has received honoraria from Kite\/Gilead, Novartis, Bristol-Myers Squibb\/Celgene, Incyte, Janssen, MSD, Takeda, Amgen, Abbvie, and Roche; and is a member on an entity\u2019s Board of Directors or advisory committees of Kite\/Gilead, Novartis, Bristol-Myers Squibb\/Celgene, Tessa Therapeutics, Abbvie and Roche. GM has received honoraria from Gilead, BMS, Novartis. BT received honoraria from Abbvie, BMS, Lilly, Kite\/Gilead and Incyte; travel accommodation from Kite\/Gilead, Roche, Abbvie, Incyte. LV has received honoraria from: Kite\/Gilead, acted as consultant for Pixilib and Genmab; received hospitality from MSD France, Siemens Healthcare, Qualimedis, General Electrics and Sanofi Aventis. CBM has received honoraria from Gilead, Novartis, Pierre Fabre. SLG. LY held membership on the board of directors or advisory committees of, and received research funding from, AbbVie, AstraZeneca, Janssen, Roche, BeiGene, BMS\/Celgene, and Gilead\/Kite. R.D.B. served as a scientific advisory board member for Novartis, Kite\/Gilead, Janssen, and BMS; was a conference speaker for Novartis, Kite\/Gilead, and AbbVie; and received travel accommodation funds from Kite\/Gilead. Other authors declared no competing interests regarding this work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}